Novartis has awarded Jacobs Engineering Group a contract to expand the company's biotechnology center in Huningue, France to increase monoclonal antibody (mAb) production capacity in a project worth $100 million. The project is scheduled to be completed in four years.

Jacobs is providing engineering, procurement, and construction management services to increase mAb production capacity by 70% and create a second purification line for the simultaneous production of multiple drugs. The expansion will include the addition of mammalian cell culture bioreactors to the site.

Source: Jacobs Engineering Group